Press Release : Lupin’s Namuscla(R) (mexiletine) is recommended by NICE for treatment of symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM)

FOR UK MEDICAL AND TRADE MEDIA ONLY
Lupin’s Namuscla(R) (mexiletine) is recommended by NICE for treatment of symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM)
Slough, UK, 4 November 2021: Global pharma major Lupin today announces that the National Institute for Health and Care Excellence (NICE) has issued the Final Appraisal Determination (FAD) recommending the routine funding of Namuscla (mexiletine) in England and Wales.

Read the source article at Stock Market Quotes and News
2021-11-04 12:32:07